Radiopharmaceutical developer IsoRay Medial is launching the brand introduction of Proxcelan, its proprietary Cesium-131 prostate cancer brachytherapy seeds, at the 2007 American Association of Physicists in Medicine (AAPM) conference in Minneapolis this week, according to the Richland, Wash.-based subsidiary of IsoRay.
IsoRay Medical said it will expand the marketing of its Proxcelan seeds used in low dose radiation (LDR) brachytherapy for prostate cancer. The firm said the launch of the Proxcelan brand will likely begin the development of a “family” of brands reflecting expanded medical applications of Cesium-131 as well as the development and marketing of other medical isotopes by the company.
Prostate seed brachytherapy is a common procedure in which seeds containing isotopes emitting low-dose radiation are implanted in and around a cancerous tumor to kill cancer cells. Approximately 60,000 procedures are conducted each year in the United States, the company said.
Although IsoRay Medical’s Proxcelan seeds have been used exclusively for the treatment of prostate cancer to date, the technology received U.S. Food and Drug Administration 510(k) clearance in March 2003 for the treatment of malignant disease (such as head and neck, brain, breast and prostate cancer).
The U.S. Centers for Medicare and Medicaid Services have established a specific reimbursement code for Proxcelan seeds, and insurance companies also cover the cost of the brachytherapy procedure, according to IsoRay Medical.